Scope of application of ivonib (Tosuvo) in solid tumors or other cancers

Ivosidenib (Ivosidenib) is mainly an oral small molecule IDH1 inhibitor, initially used to treat acute myeloid leukemia (AML) carrying IDH1 mutations. In recent years, with the in-depth research on IDH1 mutations in solid tumors, the application scope of ivonib has gradually expanded to a variety of solid tumor types, including cholangiocarcinoma (cholangiocarcinoma), glioblastoma (glioblastoma) and certain soft tissue tumors. Its mechanism of action is to block abnormalities by selectively inhibiting the mutated IDH1 enzyme. D‑2‑hydroxyglutarate (2‑HG) accumulates, thereby restoring normal cell differentiation and metabolism and inhibiting tumor proliferation.

Avosidenib has demonstrated significant antitumor activity in cholangiocarcinoma, particularly in unresectable or metastatic cases. Clinical studies have shown that for patients with cholangiocarcinoma carrying IDH1 mutations, the use of ivonib can prolong progression-free survival (PFS) and overall survival (OS) and improve quality of life. Some single-arm multi-center studies have shown that the drug can achieve partial remission (PR) or stable disease (SD) in some patients, and is well tolerated. The main side effects are fatigue, nausea and hematological changes.

Avosidenib has also shown potential in brain tumors such as glioblastoma. Since IDH1 mutations are common in low-grade gliomas, ivonib can slow down the dedifferentiation and invasion of tumor cells by inhibiting the excessive accumulation of 2‑HG . Early I/II clinical trial results show that some patients have reduced or stabilized tumor volume, suggesting that it can be used as a targeted treatment option for glioma patients, especially for cases with poor tolerance or recurrence of traditional radiotherapy and chemotherapy.

In addition, ivonib is used in other drugs IDH1 Applications are also being explored in mutation-related solid tumors, including soft tissue sarcomas, osteosarcomas and some digestive system tumors. With the accumulation of more multi-center clinical trial data, it is expected that the indications of ivonib in the treatment of solid tumors may be further expanded, providing personalized and targeted treatment options for patients with IDH1 mutations. Its overall safety and tolerability are good, and combined with genetic testing to guide medication, it can achieve precise anti-tumor treatment.

Keyword tags:

Ivonib, solid tumors, application scope, cholangiocarcinoma, glioblastoma, IDH1Mutation, targeted therapy, clinical trial

Reference materials:https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib